Protective Mechanisms of Prenatal Aspirin Therapy on Maternal Vascular Dysfunction Following Preeclampsia

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

Preeclampsia is a pregnancy disorder affecting \ 5-10% of pregnancies in the United States. Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. Low dose aspirin (LDA; 75-150mg/daily) is currently the most effective and clinically accepted therapy for reducing preeclampsia prevalence in women at high risk for developing the syndrome. The purpose of this study is to interrogate the mechanisms by which LDA therapy mitigates persistent vascular dysfunction in postpartum women who have had preeclampsia. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) they examine the blood vessels in a dime-sized area of the skin in women who have had a history of preeclampsia. As a compliment to these measurements, they also draw blood from the subjects and isolate the inflammatory cells.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: t
View:

• 18 years or older,

• 12 weeks to 5 years postpartum

• and one of the following:

‣ women who had a normal pregnancy and did not use low does aspirin (LDA) during pregnancy,

⁃ women who had a normal pregnancy and used LDA during pregnancy,

⁃ women who had preeclampsia and did not use LDA during pregnancy,

⁃ women who had preeclampsia and used LDA during pregnancy.

Locations
United States
Iowa
University of Iowa
RECRUITING
Iowa City
Contact Information
Primary
Anna Reid-Stanhewicz, PHD
anna-stanhewicz@uiowa.edu
319-467-1732
Time Frame
Start Date: 2023-01-03
Estimated Completion Date: 2027-07-30
Participants
Target number of participants: 60
Treatments
Experimental: assessment of microvascular function
The investigators use intradermal microdialysis to deliver acetylcholine, acetylcholine + L-NAME, endothelin-1, endothelin-1 + BQ-788, and endothelin-1 + BQ-123 to the cutaneous microvasculature.
Related Therapeutic Areas
Sponsors
Leads: Anna Stanhewicz, PhD

This content was sourced from clinicaltrials.gov